SCHEMBL29655546

SCHEMBL29655546

O=C(O)c1cc2c(F)cc(F)cc2[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 3/20 0.63
KDM4E B2RXH2 5/20 0.56
HSD17B10 Q99714 4/20 0.56
HPGD P15428 4/20 0.56
LMNA P02545 3/20 0.56
ALDH1A1 P00352 3/20 0.56
CYP2C19 P33261 2/20 0.56
PDPK1 O15530 1/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
APEX1 P27695 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
GRIN1 Q05586 2/20 0.51
RHEB Q15382 4/20 0.49
IDO1 P14902 3/20 0.46
TDO2 P48775 3/20 0.46
CNR1 P21554 1/20 0.44
MEN1 O00255 2/20 0.44
MAPK1 P28482 2/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144892 1.00 EIF4A3 (0.63) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL30536689 0.86 EIF4A3 (0.49) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL24448445 0.85 EIF4A3 (0.47) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL30147573 0.85 EIF4A3 (0.47) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL16234661 0.85 EIF4A3 (0.51) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL30067362 0.85 EIF4A3 (0.47) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL15515831 0.84 GRIN1 (0.70) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL21624049 0.84 KDM4E (0.51) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL20505503 0.84 EIF4A3 (0.54) EIF4A3KDM4EHSD17B10HPGDLMNA
SCHEMBL29974385 0.84 GRIN1 (0.70) EIF4A3KDM4EHSD17B10HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587433-A1 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS Takeda Pharmaceutical Company Limited (JP) 2025-07-23 EP disclosed
WO-2025101881-A1 HETEROATOM CONTAINING PEPTIDOMIMETICS TARGETING VIRAL PROTEASES EMORY UNIVERSITY (US) 2025-05-15 WO disclosed
CN-119638737-A Macrocyclic compounds and their use in medicine 广东东阳光药业股份有限公司 2025-03-18 CN disclosed
WO-2025036439-A1 MULTICYCLIC COMPOUNDS AND THEIR USE AS PI3K ALPHA INHIBITORS LAEKNA PHARMACEUTICAL NINGBO CO., LTD. (CN) 2025-02-20 WO disclosed
WO-2024059087-A1 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-21 WO disclosed
CN-111886234-B Heterocyclic mitochondrial activity inhibitors and uses thereof 蒙特利尔大学 2023-12-15 CN disclosed
CN-116813697-A Halogenated benzene ring-spiro compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-09-29 CN disclosed
CN-116621917-A Difluoro indole-spiro compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-08-22 CN disclosed
CN-116348477-A Functionalized peptides as antiviral agents 英安塔制药有限公司 2023-06-27 CN disclosed
CN-116178367-A Application of benzoheterocycle compounds in treatment or prevention of hepatitis B 中以海德人工智能药物研发股份有限公司 2023-05-30 CN disclosed
WO-2023086350-A1 ALKYNE-CONTAINING ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2023-05-19 WO disclosed
EP-4161916-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-04-12 EP disclosed
EP-4149945-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-03-22 EP disclosed
US-20230040909-A1 INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2023-02-09 US disclosed
CN-115551864-A Substituted tricyclic amides, analogs thereof, and methods of using the same 爱彼特生物制药公司 2022-12-30 CN disclosed
CN-114671795-B Indole compound, preparation method and application thereof in aldehyde ketone detection 中国环境科学研究院 2022-08-19 CN disclosed
EP-4034103-A1 INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS The Global Alliance for TB Drug Development, Inc. (US) 2022-08-03 EP disclosed
WO-2022109363-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2022-05-27 WO disclosed
CN-114524821-A Novel spiropyrrolidine derived antiviral drugs 英安塔制药有限公司 2022-05-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040909-A1 INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS IDO1, IDO2, INMT EIF4A3 3180/4885KDM4E 1303/4885HSD17B10 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.